- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:35 | Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing companies over the top | ||
| Do | After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb tried to ban | ||
| Do | Biopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+ | ||
| Do | Forbion spotlights late-stage plays, carves out new €250M growth fund | ||
| Do | Merck expands scope of Zymeworks antibody alliance, adding close to $900M in milestones | ||
| Do | The home run count: The $100M+ mega-round boom in biotech inspired a $6.7B feeding frenzy - so far this year | ||
| Do | NIH kicks off Covid-19 vaccine, monoclonal antibody research network | ||
| Do | Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D | ||
| Do | Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player | ||
| Do | Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace | ||
| Do | Covid-19 roundup: After promising US its summer supply, Gilead in talks with EU over remdesivir access; First inhaled remdesivir study underway | ||
| Mi | A new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that be reflected in the price? | ||
| Mi | Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics | ||
| Mi | Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs | ||
| Mi | Concert gets BTD for alopecia drug, setting up a late-stage showdown with giant rival Pfizer | ||
| Mi | 'Fundamentally different' from Portola, Dutch biotech lands €32M to steer anti-anticoagulant through the clinic | ||
| Mi | FDA bars the door - for now - against Merck's star cancer drug after Roche beat them to the punch | ||
| Mi | Biogen shares spike as execs complete a delayed pitch for their controversial Alzheimer's drug - the next move belongs to the FDA | ||
| Mi | Covid-19 roundup: EU backs Osivax's pursuit of a universal vaccine to fight Covid-19 | ||
| Mi | Merck dangles up to $425 million to team with Flagship's Foghorn Therapeutics on drugging the shape of DNA | ||
| Mi | John Reed brings NK cells into Sanofi's CD38 rivalry with Darzalex - and offers thumbs up for Kiadis' new focus | ||
| Mi | GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada | ||
| Mi | Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent? | ||
| Di | Boehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan | ||
| Di | AlloVir tests how much an antiviral biotech can reap in a pandemic stock market |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
